Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences
Bull Case

Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

• Zacks Research recently upgraded Gilead Sciences, Inc. to a Strong-Buy rating and raised its full-year 2028 earnings per share estimate to $9.66, signaling strong confidence in the company's long-term profitability and growth trajectory.
• The stock is currently trading at $151.22, which is below the consensus analyst price target of $158.04, suggesting there is still room for upside potential as the market digests recent positive earnings surprises and product approvals.
• Gilead Sciences, Inc. reported a significant earnings beat in its most recent quarter, posting an EPS of ($6.75) compared to the consensus estimate of ($7.25), while also exceeding revenue expectations with $7.80 billion in sales, demonstrating strong operational execution.
• The company recently received FDA approval for Bixlenvo, a new single-tablet treatment for HIV, which expands its portfolio in a high-growth area and provides a new catalyst for revenue growth in its core antiviral business.
• With a low beta of 0.33, Gilead Sciences, Inc. offers a defensive investment profile that may provide stability and lower volatility compared to the broader market, making it an attractive option for risk-averse investors seeking exposure to the biotechnology sector.